PROVAL #3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROVAL #3 (PROVAL #3).
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
| Metabolism | Acetaminophen: primarily hepatic via glucuronidation and sulfation, minor CYP2E1 and CYP3A4. Butalbital: hepatic via hydroxylation and glucuronidation, induces CYP450 enzymes. Caffeine: hepatic via CYP1A2 (major) and CYP3A4 (minor). |
| Excretion | Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites. |
| Half-life | 4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours). |
| Protein binding | 92–95% primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.0–3.0 L/kg, indicating extensive tissue distribution beyond total body water. |
| Bioavailability | Oral: 65–75% (first-pass metabolism). IM: 90–100%. IV: 100%. |
| Onset of Action | Oral: 30–60 minutes; IV: 5–10 minutes; IM: 15–30 minutes. |
| Duration of Action | 4–6 hours for oral and IM; 2–4 hours for IV; clinical effect correlates with plasma concentrations above minimum effective concentration. |
| Molecular Weight | 293.36 |
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
| Dosage form | CAPSULE |
| Renal impairment | Not recommended for use in patients with GFR <30 mL/min. For GFR 30-60 mL/min, reduce dose to 1 tablet every 6 hours; maximum 4 tablets per day. |
| Liver impairment | Contraindicated in Child-Pugh class C. For class A or B, limit to 1 tablet every 6 hours; maximum 4 tablets per day. |
| Pediatric use | Not recommended for children under 12 years. For ages 12-18, 1 tablet orally every 6 hours as needed; maximum 4 tablets per day. |
| Geriatric use | Start at 1 tablet every 6 hours; maximum 4 tablets per day. Monitor renal function and avoid in those with GFR <30 mL/min. |
| 1st trimester | Limited data in humans; animal studies have shown teratogenic effects at high doses. Use only if potential benefit justifies risk. |
| 2nd trimester | No known risk of fetal organogenesis in second trimester, but monitor fetal growth due to potential for adverse effects. |
| 3rd trimester | May cause premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for PROVAL #3 (PROVAL #3).
| Placental transfer | Crosses placenta in animal studies; human data limited but likely similar. Molecular weight < 500 Da suggests significant transfer. |
| Breastfeeding | Excreted into breast milk in low concentrations; however, due to potential for serious adverse effects in neonates, avoid use in breastfeeding women. If used, monitor infant for drowsiness, respiratory depression, and poor feeding. |
■ FDA Black Box Warning
Acetaminophen may cause severe liver injury, potentially fatal; do not exceed 4 grams per day (or less if hepatic impairment or alcohol use).
| Serious Effects |
Hypersensitivity to active ingredient or any excipientSevere hepatic impairment (Child-Pugh C)Concurrent use of MAO inhibitors or within 14 days of discontinuationBradycardia or heart block without pacemakerUncontrolled congestive heart failure
| Precautions | Hepatotoxicity with acetaminophen overdose; sedation and respiratory depression with butalbital; caffeine may exacerbate anxiety, insomnia, or cardiac conditions; risk of drug dependence with barbiturates. |
| Food/Dietary | Avoid alcohol. High-fat meals may increase absorption of propoxyphene, potentiating CNS depression. Grapefruit juice may inhibit CYP3A4 metabolism, raising propoxyphene levels. |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | PROVAL #3 contains butalbital (C-II), acetaminophen, and caffeine. Butalbital is pregnancy category D; associated with neonatal withdrawal and floppy infant syndrome if used in 3rd trimester. Acetaminophen is category B; risk only with overdose. Caffeine is category C; limited data suggests no major malformations but avoid high doses. 1st trimester: possible association with neural tube defects (butalbital). 2nd and 3rd trimesters: risk of preterm labor, low birth weight, neonatal sedation, withdrawal (butalbital). Avoid in labor due to neonatal respiratory depression. |
| Fetal Monitoring | Monitor maternal CNS depression, respiratory status, hepatic function (acetaminophen) and caffeine levels. Fetal monitoring: nonstress test and biophysical profile if used chronically. Neonatal monitoring: observe for signs of withdrawal (irritability, seizures) and respiratory depression. |
| Fertility Effects | Butalbital may induce hepatic enzymes affecting sex hormones; potential reversible menstrual irregularities and reduced fertility. Acetaminophen: no known significant fertility effects. Caffeine: high intake may delay conception; avoid >200–300 mg/day. |
| Clinical Pearls | PROVAL #3 is a combination analgesic containing propoxyphene (a weak opioid) and acetaminophen. It is no longer marketed in the US due to cardiac toxicity (QT prolongation) and risk of fatal overdose. Avoid in patients with renal impairment as accumulation of norpropoxyphene metabolite increases arrhythmia risk. Monitor for respiratory depression and seizures at high doses. |
| Patient Advice | Do not exceed recommended dose; severe liver damage or fatal heart rhythm problems can occur. · Avoid alcohol while taking this medication. · Do not drive or operate machinery until you know how this drug affects you. · Seek emergency care if you experience chest palpitations, fainting, or difficulty breathing. · Discontinue and contact your doctor if you develop jaundice or dark urine (signs of liver injury). |